Login to Your Account


Carsgen, a Chinese developer of cancer therapies, announced its completion of an undisclosed series A financing led by China-based health care private equity fund BVCF Management Ltd. The proceeds will initiate the clinical trials of Carsgen's lead therapeutic.

Just six months after revealing a $10.3 million private placement to back development of a once-shelved therapy, Corbus Pharmaceuticals Holdings Inc. is preparing to submit an IND application to jump straight into a phase IIa trial of Resunab.

DUBLIN – Glionova AB, a Swedish start-up exploiting a novel mechanism of action in cancer, raised SEK42 million (US$5.7 million) in a series A round to take forward its lead drug, GLN-1001, which is in development for glioblastoma.
More NEWCO NEWS Headlines

Cast Your Vote

Has biotech’s bubble burst?: